Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,119 shares of the biopharmaceutical company’s stock after purchasing an additional 2,643 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Alnylam Pharmaceuticals were worth $14,262,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 1.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 281,793 shares of the biopharmaceutical company’s stock valued at $92,634,000 after buying an additional 3,136 shares during the period. Independent Financial Group LLC acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $208,000. Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $1,811,000. Marks Group Wealth Management Inc acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth $546,000. Finally, MASTERINVEST Kapitalanlage GmbH purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at $390,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Citigroup initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Finally, HC Wainwright upped their price target on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $455.31.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $267.47 on Monday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $266.43 and a 52-week high of $495.55. The firm has a market cap of $35.71 billion, a PE ratio of 73.08 and a beta of 0.27. The company’s 50 day moving average is $294.16 and its two-hundred day moving average is $320.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.44) earnings per share. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.